Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01775553 · ClinicalTrials.gov registry record · Phase 2
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
A Phase 2 study, sponsored by Ajai Chari.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01775553: Completed Phase 2 study, sponsored by Ajai Chari.
NCT01775553 is a Phase 2 study that has completed, run by Ajai Chari. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01775553, a Phase 2 study, has completed, sponsored by Ajai Chari.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and activity of the investigational drug known as carfilzomib in the treatment of multiple myeloma (MM) when it is given at doses above the usual dose after the standard dosing has become ineffective. The other purpose of this study is to understand what causes the multiple myeloma to become resistant to carfilzomib and whether this can be overcome in the laboratory.
Interventions
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01775553
The ClinicalTrials.gov registry entry for NCT01775553 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ajai Chari, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carfilzomib is the first listed.
NCT01775553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01775553 about?
NCT01775553 is a clinical study titled "Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib". The purpose of this study is to determine the safety and activity of the investigational drug known as carfilzomib in the treatment of multiple myeloma (MM) when it is given at doses above the usual dose after the standard dosing has become ineffective. The other purpose of this study is to understa...
What is the current status of trial NCT01775553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2013-09. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01775553?
The interventions under investigation include: Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT01775553?
This trial is sponsored by Ajai Chari, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.